Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Ouabain-induced cochlear nerve degeneration: synaptic loss and plasticity in a mouse model of auditory neuropathy.

Journal of the Association for Research in Otolaryngology : JARO | 2014

Ouabain application to the round window can selectively destroy type-I spiral ganglion cells, producing an animal model of auditory neuropathy. To assess the long-term effects of this deafferentation on synaptic organization in the organ of Corti and cochlear nucleus, and to ask whether surviving cochlear neurons show any post-injury plasticity in the adult, we quantified the peripheral and central synapses of type-I neurons at posttreatment times ranging from 1 to 3 months. Measures of normal DPOAEs and greatly reduced auditory brainstem responses (ABRs) confirmed the neuropathy phenotype. Counts of presynaptic ribbons and postsynaptic glutamate receptor patches in the inner hair cell area decreased with post-exposure time, as did counts of cochlear nerve terminals in the cochlear nucleus. Although these counts provided no evidence of new synapse formation via branching from surviving neurons, the regular appearance of ectopic neurons in the inner hair cell area suggested that neurite extension is not uncommon. Correlations between pathophysiology and histopathology showed that ABR thresholds are very insensitive to even massive neural degeneration, whereas the amplitude of ABR wave 1 is a better metric of synaptic degeneration.

Pubmed ID: 24113829 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

None found

Associated grants

  • Agency: NIDCD NIH HHS, United States
    Id: R01 DC 00188
  • Agency: NIDCD NIH HHS, United States
    Id: R01 DC012058
  • Agency: NIDCD NIH HHS, United States
    Id: R01 DC009836
  • Agency: NIDCD NIH HHS, United States
    Id: P30 DC005209
  • Agency: NIDCD NIH HHS, United States
    Id: R01 DC007174
  • Agency: NIDCD NIH HHS, United States
    Id: P50 DC000422
  • Agency: NIDCD NIH HHS, United States
    Id: R01 DC000188
  • Agency: NIDCD NIH HHS, United States
    Id: P30 DC05209

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Anti-VGlut1 Antibody (antibody)

RRID:AB_10673111

This monoclonal targets VGlut1 neurotransmitter transporter

View all literature mentions

Anti-PSD-95 Antibody (antibody)

RRID:AB_10698024

This monoclonal targets PSD-95 MAGUK scaffolding protein

View all literature mentions

Anti-VGlut1 Antibody (antibody)

RRID:AB_2187693

This monoclonal targets VGlut1

View all literature mentions

Anti-PSD-95 Antibody (antibody)

RRID:AB_2292909

This monoclonal targets PSD 95

View all literature mentions